Alexandria Real Estate Stock Drops After Class Action Lawsuit
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 03 Dec 25
Source: PRnewswire
Alexandria Real Estate Equities Inc's stock fell by 5.07%, crossing down the 5-day SMA amid negative market sentiment.
The decline follows the announcement of a class action lawsuit against the company due to disappointing Q3 earnings, which revealed a significant impairment charge and lowered guidance. Investors are concerned about the company's financial transparency and future performance.
This legal action could further impact Alexandria's market reputation and investor confidence, potentially leading to more volatility in its stock price as the company navigates these challenges.
Analyst Views on ARE
Wall Street analysts forecast ARE stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for ARE is 51.53 USD with a low forecast of 15.84 USD and a high forecast of 67.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
15 Analyst Rating
4 Buy
11 Hold
0 Sell
Moderate Buy
Current: 54.610
Low
15.84
Averages
51.53
High
67.00
Current: 54.610
Low
15.84
Averages
51.53
High
67.00
About ARE
Alexandria Real Estate Equities, Inc. is a life science real estate investment trust. The Company is an owner, operator and developer of collaborative life science, agricultural technology (agtech), and advanced technology mega campuses in AAA innovation cluster locations, including Greater Boston, the San Francisco Bay Area, New York City, San Diego, Seattle, Maryland, and Research Triangle. The Company, through its venture capital platform, provides strategic capital to life science, agrifoodtech, climate innovation, and technology companies. Its tenants include multinational pharmaceutical companies; public and private biotechnology companies; life science product, service and medical device companies; digital health, technology, and agtech companies; academic and medical research institutions; United States government research agencies; non-profit organizations, and venture capital firms. It has a Labspace asset base predominantly concentrated in markets with barriers to entry.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
